chelation

(redirected from Chelation therapy)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

chelation

[kē′lā·shən]
(organic chemistry)
A chemical process involving formation of a heterocyclic ring compound which contains at least one metal cation or hydrogen ion in the ring.
References in periodicals archive ?
Some proponents of chelation therapy say that it can improve blood flow in the arteries by removing the calcium from plaque that has built up on the artery walls.
Richard Plumb, DO, of Troy, Ohio, presented increasingly persuasive evidence on cardiovascular diseases treated by chelation therapy and troubling details on lead, mercury, cadmium, and arsenic toxicities.
Aminzadeh, "Thyroid function in major thalassemia patients: Is it related to height and chelation therapy?" Caspian Journal of Internal Medicine, vol.
Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
These patients were on regular blood transfusion with chelation therapy (desferroxamine injections).
Laboratory data On day 1 of On day 19 after Normal range admission chelation therapy Hemoglobin 9.4g/dL 11.5 g/dL 13.5-17.5 Hematocrit 27.9% 42% 41-53% AST 57 U/L 32 U/L 0-37 U/L ALT 87U/L 40 U/L 0-40 U/L Blood lead level 62.8 g/dL 31 g/dL <40 [micro]g/dL Urine delta-ALA 81.8 mg/L nil <7mg/L/24hr Urine PBG 1.0 mg/L nil <4mg/L/24hr ALT = alanine aminotransferase; AST = aspartate aminotransferase; PBG = porphobilinogen; ALA = aminolevulinic acid.
These finding emphasizes the importance of monitoring of thyroid function in all hypertransfused thalassemic patients, particularly who received suboptimal chelation therapy.
As per published protocol, Chelation therapy dose adjustment is based on kidney function and other parameters and is administered intravenously once or twice weekly for 20-30 treatments.
[3-10.08 yrs.]; 92% children were on irregular oral chelation therapy. The average duration of receiving chelation was 3.29 yrs.
Due to the persisting elevated Co/Cr blood levels (Co above 20 mcg/L and Cr above 7 mcg/L) a chelation therapy with oral high-dose NAC (300 mg/kg/day for 10 days) was performed in November 2014.
(3,4) However, very few authors have investigated the ototoxic effects of chelation therapy in |3-thalassemia.
Methodology: This study included 100 b-thalassemia major patients who were diagnosed by Hb electrophoresis and were receiving regular blood transfusions for anemia and chelation therapy for prevention of iron overload related complications.